Immunotherapy plus chemo and radiation shows promise for rare thymic cancer
NCT ID NCT07479628
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests whether combining the immunotherapy drug adebrelimab with chemotherapy and radiation before surgery can help shrink tumors in people with locally advanced thymic carcinoma. About 31 participants will receive the treatment, then have surgery if the tumor becomes removable. After surgery, they'll get more chemotherapy, radiation, and up to a year of adebrelimab. The study aims to see how well the tumor responds and whether the treatment is safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Adebrelimab (an immunotherapy drug) plus chemotherapy (albumin-bound paclitaxel and cisplatin) and radiation therapy
What this could lead to
If successful, this combination could shrink tumors enough to allow surgery and improve long-term control of thymic carcinoma.
What could go wrong
This is a small, early-phase trial with only 31 participants, so results may not apply to everyone. The combination of immunotherapy, chemotherapy, and radiation can cause significant side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYMIC CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••